title: Spectral domain optical coherence tomography features of multiple subfoveal retinal pigment epithelial tears after intravitreal bevacizumab.
abstract: Retinal pigment epithelial (RPE) tear has been described to occur spontaneously, after laser photocoagulation and in recent times, after intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents. In the latter case, the rapid contraction of the choroidal vascular membrane underneath a serous RPE detachment is believed to be the underlying cause. Preservation of good visual acuity after the occurrence of RPE tear with continued use of intravitreal VEGF agents has been reported. In this case report, we describe the occurrence of multiple RPE tears with the use of intravitreal bevacizumab and also correlate the preservation of visual acuity with features seen on spectral domain optical coherence tomography.
authors.affiliation: Department of Ophthalmology, University of Florida-College of Medicine, Jacksonville, FL, USA. kchalam@jax.ufl.edu
authors.forename: Kakarla V
authors.initials: KV
authors.lastname: Chalam
authors.forename: Ravi K
authors.initials: RK
authors.lastname: Murthy
authors.forename: Shailesh K
authors.initials: SK
authors.lastname: Gupta
authors.forename: Vikram S
authors.initials: VS
authors.lastname: Brar
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D012167:Retinal Perforations / Q000139:chemically induced* / Q000175:diagnosis*; D041623:Tomography, Optical Coherence; D014786:Vision Disorders / Q000209:etiology; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab